Yale School of Medicine researchers analyzed patients and families affected by early-onset coronary artery disease to uncover mutations in CELA2A.
Reuters reports that on the launch of Verve Therapeutics, a biotech focused on using gene editing to treat cardiovascular disease.
Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.
The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
The partnership will allow people to see their genetic risk with other health data that Seqster pulls from electronic health records and wearables.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.
Researchers compared findings from genome-wide association studies for 62 traits or conditions with genes implicated in 20 Mendelian disorder types, uncovering new ties.
The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of the test as an LDT.
In Nature this week: statistical method for overcoming case-control imbalance issues, and more.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.